Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Savara
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Savara Obtains Global Rights to Develop and Commercialize Apulmiq
Details : Under the terms of the agreement, Savara has obtained the worldwide rights to develop and commercialize Apulmiq.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Ciprofloxacin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Savara
Deal Size : Undisclosed
Deal Type : Licensing Agreement